ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.
- Open access
ALG-055009 significantly reduces liver fat in non-cirrhotic adults with MASH, with up to 33.2% relative decrease at higher doses in a phase 2a trial.
- Why it matters: Effective treatments for metabolic dysfunction-associated steatohepatitis (MASH) are limited, and reducing liver fat is crucial to prevent disease progression and improve patient outcomes.
- What they did: The study involved 102 adults with presumed MASH, randomly assigned to receive varying doses of ALG-055009 or placebo for 12 weeks, measuring liver fat change via MRI-PDFF.
- The result: Higher doses of ALG-055009 led to significant liver fat reductions with acceptable safety profiles, supporting further research into its potential as a MASH therapy.